Among approved CRBN-binding drugs, lenalidomide is currently widely used for not only multiple myeloma but also MDS 5q- syndrome21, mantle cell lymphoma22, and follicular lymphoma23. This evidence concerns the gene CRBN and plasma cell myeloma.